Hiv-1 Gp120

Overview

As of December 2007 approximately 33 million individuals worldwide were infected with HIV/AIDS. Each year since the identification of AIDS in 1981 the number of people living with HIV worldwide has increased, and since 1981 HIV/AIDS has caused the death of approximately 25 million individuals. HAART (Highly Active Anti-Retroviral Therapy, or the simultaneous utilization of multiple drugs that inhibit multiple HIV targets) has demonstrated clinical utility against HIV/AIDS, but multi-drug resistant viral strains ...
See more details below
This Paperback is Not Available through BN.com
Sending request ...

More About This Book

Overview

As of December 2007 approximately 33 million individuals worldwide were infected with HIV/AIDS. Each year since the identification of AIDS in 1981 the number of people living with HIV worldwide has increased, and since 1981 HIV/AIDS has caused the death of approximately 25 million individuals. HAART (Highly Active Anti-Retroviral Therapy, or the simultaneous utilization of multiple drugs that inhibit multiple HIV targets) has demonstrated clinical utility against HIV/AIDS, but multi-drug resistant viral strains are emerging. Necessary to increasing and extending the efficacy of HAART will be the utilization of novel HIV targets such as the HIV-1 envelope protein gp120. As described within this study we have incorporated, scaled-up, and optimized existing gp120 production techniques and developed novel, large-scale purification techniques. We have refined the characterization of the monomeric gp120 structure using differential scanning calorimetry and have refined the characterization of the binding of gp120 to soluble CD4 and chemokine coreceptor surrogate monoclonal antibody 17b using isothermal titration calorimetry. We have used these data not only to more fully investigate the structure of gp120 but also to develop thermodynamic and structural guidelines for development of competitive and allosteric inhibitors of gp120. Further, building upon the discovery by other research groups of the pre-clinical gp120 binding compounds NBD-556 and BMS-806, we have thermodynamically characterized the interactions of NBD-556 and BMS-806 with gp120 and the effects of these interactions upon receptor binding. Through application of our thermodynamic guidelines we have determined that NBD-556 is a competitive inhibitor of gp120 and that BMS-806 is a gp120 inhibitor with allosteric inhibitory properties. Thermodynamic and mechanistic understanding of interactions of each of these compounds with gp120 will not only aid in the derivatization of these compounds but also generate a more complete understanding of the structure and mechanism of envelope-mediated cell entry. Thermodynamic and structural characterization of the interactions of gp120 inhibitors with gp120 and inhibitor-induced perturbations of receptor binding are critical tools towards optimization of these and future gp120 inhibitors.
Read More Show Less

Product Details

  • ISBN-13: 9781244014282
  • Publisher: BiblioLabsII
  • Publication date: 9/11/2011
  • Pages: 148
  • Product dimensions: 7.44 (w) x 9.69 (h) x 0.32 (d)

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)